Effects of switching pravastatin to cerivastatin on C-reactive protein, butyrylcholinesterase, and lipids

References

• Morrow DA, Ridker PM. C-reactive protein, inflammation, and coronary risk. Med Clin North Am 2000;84:149–61
   PubMed Web of Science ®Google Scholar
• Patel VB, Robbins MA, Topol EJ. C-reactive protein: a ‘golden marker’ for inflammation and coronary artery disease. Cleve Clin J Med 2001;68:521–33
   Google Scholar
• Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844–850
   PubMed Web of Science ®Google Scholar
• Kullo IJ, Gau GT, Tajik AJ. Novel risk factors for atherosclerosis. Mayo Clin Proc 2000;75:369–80
   PubMed Web of Science ®Google Scholar
• Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. J Am Med Assoc 2001;285:2481–5
   Google Scholar
• Alcantara VM, Chautard-Freire-Maia EA, et al. Butyrylcholinesterase activity and risk factors for coronary artery disease. Scan J Clin Lab Invest 2002;62:399–404
   PubMed Web of Science ®Google Scholar
• Kutty KM, Payne RH. Serum pseudocholinesterase and very-low-density lipoprotein metabolism. J Clin Lab Anal 1994;8:247–50
   PubMed Web of Science ®Google Scholar
• Rustemeijer C, Schouten JA, Voerman HJ, Beynen AC, Donker AJM, Heines, RJ. Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in type II diabetes mellitus? Clin Sci 2001;101:29–35
   Google Scholar
• Abbott CA, Mackness MI, Kumar S, et al. Relationship between serum butyrylcholinesterase activity, hypertriglyceridemia and insulin sensitivity in diabetes mellitus. Clin Sci 1993;85:77–81
   PubMed Web of Science ®Google Scholar
• Crook M, Haq M, Tutt P. Serum lipids, acute phase proteins and serum cholinesterase in normal subjects. Scan J Clin Lab Invest 1994;54;601–3
   Google Scholar
• Jain R, Kutty M, Huang SN, Kean K. Pseudocholinesterase/high-density lipoprotein cholesterol ratio in serum of normal persons and of hyperlipoproteinemics. Clin Chem 1983;29:1031–3
   PubMed Web of Science ®Google Scholar
• Chu MI, Fontaine P, Kutty KM, Murphy D, Redheendran R. Cholinesterase in serum and low density lipoprotein of hyperlipidemic patients. Clin Chim Acta 1978;85:55–9
   Google Scholar
• Cucuianu M, Popescu TA, Opincaru A, Haragus S. Serum pseudocholinesterase and ceruloplasmin in various types of hyperlipoproteinemia. Clin Chim Acta 1975;59:19–27
   PubMed Web of Science ®Google Scholar
• Magarian EO, Dietz AJ. Correlation of cholinesterase with serum lipids and lipoproteins. J Clin Pharmacol 1987;27:819–20
   PubMed Web of Science ®Google Scholar
• Pepys MB, Rowe IF, Baltz ML. C-reactive protein: binding to lipids and lipoproteins. Int Rev Exp Pathol 1985;27:83–111
   Google Scholar
• DeBeer FC, Soutar AK, Baltz ML, Trayner IM, Feinstein TA, Pepys MB. Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med 1982;156:230–42
   PubMed Web of Science ®Google Scholar
• Cabana VG, Gewurz H, Siegal JN. Inflammation-induced changes in rabbit CRP and plasma lipoproteins. J Immunol 1983;130:1736–42
   Google Scholar
• Cabana VG, Gewurz H, Siegel JN. Interaction of very low density lipoproteins (VLDL) with rabbit C-reactive protein. J Immunol 1982;128:2342–8
   Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230–5
   Google Scholar
• Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001;103: 1191–3
   Google Scholar
• Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 2001;77:247–53
   PubMed Web of Science ®Google Scholar
• Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933–5
   Google Scholar
• Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. J Am Med Assoc 2001;286:64–70
   PubMed Web of Science ®Google Scholar
• Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total cholesterol and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007–11
   Google Scholar
• Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95
   PubMed Web of Science ®Google Scholar
• Kinlay S, Selwyn AP. Effects of statins on inflammation in patients with acute and chronic coronary syndromes. Am J Cardiol 2003;91(Suppl):9B–13B
   Google Scholar
• Kinlay S, Timms T, Clark M, et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol 2002;89:1205–7
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002;106: 2055–60
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardio vascular disease in women. New Engl J Med 2000; 342:836–43
   PubMed Web of Science ®Google Scholar
• Hutchinson WL, Koenig W, Frohlich M, Sund M, Lowe GDO, Pepys MB. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem 2000;46:934–8
   PubMed Web of Science ®Google Scholar
• Saito M, Ishimitsu T, Minami J, Ono H, Ohrui M, Matsuoka H. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 2003;167:73–9
   PubMed Web of Science ®Google Scholar
• Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237–42
   PubMed Web of Science ®Google Scholar
• Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in ‘active’ coronary artery disease. Am J Cardiol 1990;65:168–72
   Google Scholar
• De Ferranti S, Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clin Chim Acta 2002;317:1–15
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J Am Med Assoc 2001;286: 327–34
   Google Scholar
• Darvesh S, Martin E, Walsh R, Rockwood K. Differential effects of lipid-lowering agents on human cholinesterases. Clin Biochem 2004;37:42–9
   PubMed Web of Science ®Google Scholar